LEXX (Lexaria Bioscience) Total Stockholders Equity: $4.74 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
36 GF Score
Price $10.60
GF Value $5.38
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lexaria Bioscience Total Stockholders Equity?

Lexaria Bioscience LEXX -4.27% 36 Total Stockholders Equity is $4.74 Mil as of May. 2026. GuruFocus rates LEXX with a GF Score™ of 36/100 and a GF Value™ of $5.38 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Lexaria Bioscience's Total Stockholders Equity for the quarter that ended in May. 2026 was $4.74 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Lexaria Bioscience's Book Value per Share for the quarter that ended in May. 2026 was $2.87. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Lexaria Bioscience's Debt-to-Equity for the quarter that ended in May. 2026 was 0.02.

Lexaria Bioscience  (NAS:LEXX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Lexaria Bioscience's Book Value per Share for the quarter that ended in May. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.738-0)/1.652
=2.87

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Lexaria Bioscience's Debt-to-Equity for the quarter that ended in May. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.033 + 0.054) / 4.738
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Total Stockholders Equity Related Terms

Lexaria Bioscience Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Total Stockholders Equity Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.27 7.95 3.04 8.04 2.99

Lexaria Bioscience Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.55 2.99 4.91 6.60 4.74
LEXX
36GF Score
Lexaria Bioscience Corp LEXX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $4.74 Mil mean?
Lexaria Bioscience (LEXX) has a Total Stockholders Equity of $4.74 Mil as of May. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Total Stockholders Equity too high?
Lexaria Bioscience's current Total Stockholders Equity is $4.74 Mil. Overall, Lexaria Bioscience has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Total Stockholders Equity compare to CTXR and PTN?
Lexaria Bioscience's Total Stockholders Equity of $4.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Lexaria Bioscience and its competitors. Lexaria Bioscience's current Total Stockholders Equity is $4.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.38, compared to a current price of $10.60 — trading 97% above its estimated fair value. The current Total Stockholders Equity is $4.74 Mil. Lexaria Bioscience's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Total Stockholders Equity is $4.74 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued. The current stock price of $10.60 is trading 97% above its estimated GF Value™ of $5.38. GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.

Key valuation signals for LEXX:

  • Total Stockholders Equity: $4.74 Mil
  • GF Value™: $5.38 vs. price of $10.60 (97% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
36GF Score

Get the complete analysis for LEXX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.60
Price
$5.38
GF Value